ClinicalTrials.gg
CompletedNCT00352183Updated Jul 8, 2009

Comparison of the Combination of Fenofibrate and 40 mg Simvastatin Versus 40 mg Simvastatin Monotherapy

A Phase 3 interventional study of Fenofibrate/Simvastatin and Simvastatin in Cardiovascular Diseases, sponsored by Solvay Pharmaceuticals. Completed at 67 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-07-08.

Sponsored by Solvay Pharmaceuticals (part of Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia. The overall objective of the study is to evaluate the efficacy and safety of combining fenofibrate and simvastatin in patients with mixed hyperlipidemia at risk of cardiovascular diseases.

02

Conditions studied

  • Cardiovascular Diseases

Keywords

  • Hyperlipidemia Combined
  • Combination of fenofibrate and simvastatin
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 450 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Solvay Pharmaceuticals is the lead sponsor of 86 studies on the registry; none are open to participants now.

First submitted before Solvay Pharmaceuticals became part of Abbott.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mixed dyslipidemia

Exclusion criteria

Exclusion Criteria:

  • Diabetes,
  • Known to fenofibrate or simvastatin,
  • Pregnant or lactating women,
  • to fenofibrate or simvastatin,
  • Unstable or severe cardiac disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
450 participants (actual)

Study arms

  • Experimental
    1

    Drug: Fenofibrate/Simvastatin

  • Active comparator
    2

    Drug: Simvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Triglycerides

    Time frame: 12 weeks

  2. Percent change from baseline to 12 weeks of treatment in HDL-C

    Time frame: 12 weeks

  3. Percent change from baseline to 12 weeks of treatment in LDL-C

    Time frame: 12 weeks

Secondary outcomes

  1. Percent change from baseline to 24 weeks of treatment in Triglycerides

    Time frame: 24 weeks

  2. Percent change from baseline to 24 weeks of treatment in HDL-C

    Time frame: 24 weeks

  3. Percent change from baseline to 24 weeks of treatment in LDL-C

    Time frame: 24 weeks

07

Study locations

67 sites
  • Site 204
    Adelaide, Australia
  • Site 214
    Adelaide, Australia
  • Site 203
    Bendigo, Australia
  • Site 207
    Brisbane, Australia
  • Site 208
    Brisbane, Australia
  • Site 221
    Brisbane, Australia
  • Site 202
    Burnie, Australia
  • Site 201
    Camperdown, Australia
  • Site 220
    Coffs Harbour, Australia
  • Site 218
    Daw Park, Australia
  • Site 212
    Elizabeth Vale, Australia
  • Site 217
    Fitzroy, Australia
  • Site 222
    Fremantle, Australia
  • Site 216
    Geelong, Australia
  • Site 225
    Ingleburn, Australia
  • Site 213
    Kippa-ring, Australia
  • Site 209
    Launceston, Australia
  • Site 219
    Liverpool, Australia
  • Site 223
    Malvern, Australia
  • Site 211
    Meadowbrook, Australia
  • Site 224
    Miranda, Australia
  • Site 210
    Nambour, Australia
  • Site 205
    Parkville, Australia
  • Site 206
    Sale, Australia
  • Site 215
    Sydney, Australia
  • Site 301
    Tallinn, Estonia
  • Site 302
    Tallinn, Estonia
  • Site 303
    Tallinn, Estonia
  • Site 305
    Tallinn, Estonia
  • Site 306
    Tallinn, Estonia
  • Site 304
    Tartu, Estonia
  • Site 307
    Tartu, Estonia
  • Site 603
    Balatonfured, Hungary
  • Site 605
    Budapest, Hungary
  • Site 608
    Budapest, Hungary
  • Site 604
    Gyongyos, Hungary
  • Site 602
    Gyor, Hungary
  • Site 610
    Hodmezovasarhely, Hungary
  • Site 609
    Kecskemet, Hungary
  • Site 601
    Miskolc, Hungary
  • Site 607
    Sopron, Hungary
  • Site 606
    Szekesfehervar, Hungary
  • Site 403
    Daugavpils, Latvia
  • Site 406
    Jekabpils, Latvia
  • Site 401
    Ogre, Latvia
  • Site 402
    Riga, Latvia
  • Site 405
    Riga, Latvia
  • Site 404
    Tukums, Latvia
  • Site 502
    Alytus, Lithuania
  • Site 503
    Kaunas, Lithuania
  • Site 506
    Kaunas, Lithuania
  • Site 505
    Klaipeda, Lithuania
  • Site 507
    Klaipeda, Lithuania
  • Site 508
    Palanga, Lithuania
  • Site 504
    Siauliai, Lithuania
  • Site 501
    Vilnius, Lithuania
  • Site 102
    Auckland, New Zealand
  • Site 103
    Auckland, New Zealand
  • Site 107
    Blenheim, New Zealand
  • Site 101
    Christchurch, New Zealand
  • Site 108
    Dunedin, New Zealand
  • Site 104
    Hamilton, New Zealand
  • Site 111
    Hastings, New Zealand
  • Site 106
    Nelson, New Zealand
  • Site 110
    Newtown, Wellington, New Zealand
  • Site 109
    Takapuna, Auckland, New Zealand
  • Site 105
    Tauranga, New Zealand
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2006
First posted
Jul 14, 2006
Start
Jan 2006
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Last update
Jul 8, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00352183
First posted
Jul 14, 2006
Start date
Jan 2006
Primary completion
Aug 2008
Completion
Aug 2008
Last update
Jul 8, 2009

Study contacts

Global Clinical Director Solvay
study director · Solvay Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fenofibrate · Simvastatin

Start the discussion